VIP-ellipticine derivatives inhibit the growth of breast cancer cells
| Autor: | Terry W. Moody, G. Czerwinski, Nadya I. Tarasova, Christopher J. Michejda |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Receptors Vasoactive Intestinal Polypeptide Type I Vasoactive intestinal peptide Molecular Sequence Data Breast Neoplasms Biology General Biochemistry Genetics and Molecular Biology chemistry.chemical_compound Breast cancer Internal medicine medicine Cytotoxic T cell Humans Viability assay Amino Acid Sequence Ellipticines RNA Messenger General Pharmacology Toxicology and Pharmaceutics skin and connective tissue diseases ED50 Messenger RNA General Medicine medicine.disease Molecular biology Endocrinology chemistry Receptors Vasoactive Intestinal Peptide Trypan blue Breast cancer cells Proto-Oncogene Proteins c-fos hormones hormone substitutes and hormone antagonists Cell Division Vasoactive Intestinal Peptide |
| Zdroj: | Life sciences. 71(9) |
| ISSN: | 0024-3205 |
| Popis: | The effects of vasoactive intestinal peptide (VIP)-ellipticine (E) derivatives were investigated on breast cancer cells. VIP-ALALA-E and VIP-LALA-E inhibited 125I-VIP binding to MCF-7 cells with an IC(50) values of 1 and 0.2 microM respectively. VIP-ALALA-E and VIP-LALA-E caused elevation of cAMP in MCF-7 cells with ED(50) values of 1 and 0.1 microM. VIP-LALA-E caused increased c-fos mRNA in MCF-7 cells. Radiolabeled VIP-LALA-E was internalized at 37 degrees C and delivered the cytotoxic E into MCF-7 cells. VIP-LALA-E inhibited the clonal growth of MCF-7 cells, decreased cell viability based on trypan blue exclusion and reduced 35S-methionine uptake. These results indicate that VIP-E derivatives function as breast cancer VPAC(1) receptor agonists which inhibit MCF-7 cellular viability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect